| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Neumora Therapeutics, Inc.
13G/A
Amendment 2
NMRA · 640979100
|
3.1% |
5/15/2026
Event 3/31/2026
|
|||
| K2 HealthVentures Equity Trust LLC | 3.1% | ||||
| Parag Shah | 3.1% | ||||
| Anup Arora | 3.1% | ||||
|
Neumora Therapeutics, Inc.
13G/A
Amendment 1
NMRA · 640979100
|
5.0% |
2/17/2026
Event 12/31/2025
|
|||
| K2 HealthVentures Equity Trust LLC | 5.0% | ||||
| Parag Shah | 5.0% | ||||
| Anup Arora | 5.0% | ||||
|
Alto Neuroscience, Inc.
13G/A
Amendment 1
ANRO · 02157Q109
|
2.4% |
2/17/2026
Event 12/31/2025
|
|||
| K2 HealthVentures Equity Trust LLC | 2.4% | ||||
| Parag Shah | 2.4% | ||||
| Anup Arora | 2.4% | ||||
|
Neumora Therapeutics, Inc.
13G
NMRA · 640979100
|
6.6% |
8/11/2025
Event 5/9/2025
|
|||
| K2 HealthVentures Equity Trust LLC | 6.6% | ||||
| Parag Shah | 6.6% | ||||
| Anup Arora | 6.6% | ||||
|
Alto Neuroscience, Inc.
13G
ANRO · 02157Q109
|
5.6% |
5/15/2025
Event 1/13/2025
|
|||
| K2 HealthVentures Equity Trust LLC | 5.6% | ||||
| Parag Shah | 5.6% | ||||
| Anup Arora | 5.6% | ||||
|
TScan Therapeutics, Inc.
13G/A
Amendment 3
TCRX · 89854M101
|
6.9% |
2/14/2025
Event 12/31/2024
|
|||
| K2 HealthVentures Equity Trust LLC | 6.9% | ||||
| Parag Shah | 6.9% | ||||
| Anup Arora | 6.9% | ||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.